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Diﬀuse large B-cell lymphoma represents approximately 30%–40% of all diagnoses of non-Hodgkin’s Lymphoma and may
represent up to 80% of all lymphomas that arise in the palatine tonsils. Several studies have attempted to correlate clinical,
laboratorial, and tissue factors with the prognosis of the lymphomas, such as the International Prognostic Index, the tissue
expression of some proteins, and the lymphocyte count at the time of diagnosis, as well as to correlate Epstein-Barr virus (EBV)
infectionwithworseprognoses.PatientswithpalatinetonsilDLBCL,fromSalvador,Bahia,Brazil,werestudiedinordertoidentify
prognostic factors. Twenty-four patients with DLBCL were studied. The factors that negatively inﬂuenced the patients’ survival
rates were the lymphocyte count at the time of diagnosis <1.000/mm3 and the Bcl-2 protein expression. There was no CD5
expression in these lymphomas, and neither was there an association with EBV infection.
1.Introduction
The palatine tonsils, along with the nasopharyngeal lym-
phoid tissue, the base of the tongue, and the oropharyngeal
wall make up Waldeyer’s ring. This ring is located at the
entrance of the respiratory and digestive tract, being the
second most common site of extranodal lymphomas, after
the gastrointestinal tract [1, 2]. These tumors represent
15 to 20% of all lymphomas and half of the head and
neck lymphomas. Approximately 50% of Waldeyer’s ring
lymphomas arise in the palatine tonsils in presentation, and
in approximately 20% of the cases they are bilateral [3].
Most lymphomas found in the palatine tonsils are the
B-cell type, and, of these, diﬀuse large B-cell lymphoma
(DLBCL) represents most of the cases, reaching as much as
80% in some of the groups studied [3, 4].
Although morphologically indistinct, some molecular
studies support the hypothesis that DLBCL makes up
a heterogeneous group of lymphomas that has diﬀerent
prognostic implications [5]. Classically, the International
Prognostic Index (IPI) has been used to predict the survival
of patients with DLBCL [6]; however, it is not useful
in all cases. Studies using DNA microarray analysis show
that the DLBCL gene expression proﬁle similar to B cells
germinal center would have a better clinical prognosis than
the proﬁle similar to activated B cells [5, 7]. Transposing
this gene proﬁle to a protein expression, Hans et al. [8]
proposed an algorithm to classify DLBCL patients, using
three immunohistochemical markers (CD10, Bcl-6, and
MUM1). The proﬁle that was similar to the germinal center
(GC) presented a better survival rate than the proﬁle of the
nongerminal center (non-GC). Other tissue markers, such2 ISRN Oncology
as Bcl-2, CD5, and p53 protein have been referred to as
prognosticpredictorsinDLBCL[9–11].Alymphocytecount
<1.000cells/mm3 at the time of diagnosis has recently been
described as associated with a worse prognosis in DLBCL
[12, 13].
Another controversial prognostic tissue marker has been
the detection of Epstein-Barr virus (EBV) infection in
neoplasticcells.WhileinpediatricHodgkin’sLymphomathis
infection is associated with a better prognosis [14], in adults
the infection in DLBCL seems to be associated with a worse
prognosis [15]. EBV belongs to the herpes virus family, is
transmittedthroughcontactwithsaliva,andinfectsmostlyB
lymphocytes and occasionally oropharyngeal epithelial cells.
Serum-epidemiological studies show that more than 90% of
the patients with DLBCL, worldwide, are infected with EBV
[16]. This infection has been detected in approximately 9%
of patients with DLBCL [15]. However, in head and neck
lymphomas, this index seems to be higher, reaching 90%
in Egypt [17]. In Brazil, this infection has been associated
with pediatric lymphomas originating in germinal center
cells [18], although the index of this infection in adults with
DLBCL has not yet been studied.
Considering that the use of IPI has been shown to be
insuﬃcient as the only prognostic marker in DLBCL, we
evaluated other laboratory and tissue markers in patients
with DLBCL of palatine tonsils, who came from a reference
institution for the diagnosis and treatment of patients with
cancer in Northeastern Brazil.
2. Patientsand Methods
2.1. Patient Selection. The patients were selected at the
Pathological Anatomy Service of the Aristides Maltez Hospi-
tal in Salvador, Bahia, Brazil. All patients with a diagnosis of
DLBCL of the palatine tonsils were included. The diagnoses
were carried out between January of 1999 and December of
2006, on patients with illness primary site in the tonsils, or
on those who presented the main tumor mass in the same
area.
The diagnoses were reviewed by a hematopathologist
(I.A.) according to the criteria established by the lymphoid
neoplasia classiﬁcation of the World Health Organization
2008 [19]. The clinical data were gathered from medical
chart records, and patients with incomplete medical charts
were excluded. The staging was obtained using the Ann
Arbor criteria [20], and the IPI was obtained according to
previously established parameters [6]. This current work
was approved by the Ethics Committee for Human Subjects
Research and complies with the principles of the Helsinki
Declaration.
2.2. Immunohistochemical (IHC) Study. T h et i s s u eu s e di n
the study had been set in formalin. Serial 4µms e c t i o n so f
tissueblocksweremountedonsilanizedslides,deparaphined
with xylene, and cleansed in alcohol. The streptavidin-
biotin-peroxidase technique was used, with previous, humid
heat antigen recovery. A commercially available panel of
antibodies was used (Table 1).
Table 1: Antibodies used for immunohistochemical study.
Antibody Clone Dilution Source
CD3 F7.2.38 1:100 DakoCytomation
CD5 4C7 1:50 Novocastra
CD10 56C6 1:50 Novocastra
CD20 L26 1:100 DakoCytomation
Bcl-2 124 1:50 DakoCytomation
Bcl-6 P1F6 1:20 Novocastra
MUM1 MUM1p 1:50 DakoCytomation
p53 PAb1801 1:100 Novocastra
Ki67 MIB-1 1:50 DakoCytomation
For the antibodies CD3, CD5, CD10, CD20, Bcl-2, Bcl-6,
and MUM1, the cases with more than 10% of the tumor cells
marked were considered positive. For the Ki-67 analysis, the
cases were semiquantiﬁed on a positivity scale of 0 to 100%,
according to the quantity of marked tumor cells per ﬁeld, in
an increase of 400x. The p53 protein analysis was carried out
using the Sannino and Shousha score [21].
The IHC classiﬁcation according to the Hans et al.
algorithm [8] in GC and non-GC proﬁle was carried out
usingtheC10,Bcl-6,andMUM1markers.Patientswhowere
positive for CD10 alone, or positive for CD10 and Bcl-6,
were considered as GC proﬁles. Patients who were negative
for CD10 and Bcl-6 were considered as non-GC proﬁles.
Patients who were negative for CD10 and positive for Bcl-6
were classiﬁed after the MUM1 analysis. The cases that were
negative for MUM1 were classiﬁed as GC proﬁles, and the
positive cases were classiﬁed as non-GC proﬁles.
2.3. In Situ Hybridization. In situ hybridization for the
detection of EBER 1 and 2 transcription of EBV was carried
out in RNA-free conditions, using speciﬁc probes marked
with digoxigenin, as previously described [18]. For positive
controls, tissue from patients with Burkitt lymphoma and
infectious mononucleosis was used, previously identiﬁed as
positive for EBV. The sign considered positive was located in
the nucleus.
2.4. Statistical Analyses. To compare the diﬀerence between
the two proportions, the chi-square test and Fisher exact test
were used. The diﬀerences between two means were analyzed
by the Mann-Whitney test. The Kaplan-Meier survival anal-
ysis and the log-rank test were used to study the prognostic
signiﬁcance of the utilized biomarkers. The overall survival
(OS) was calculated from the date of diagnosis to the last
evaluation, or date of death. Event-free survival (EFS) was
calculated from the date of diagnosis until date of death,
disease progression, or end of clinical followup. The P value
was considered signiﬁcant when <0.05. The SPSS software
version 16.0 was used to carry out all the calculations.
3. Results
3.1.GeneralCharacteristicsofthePatients. Duringthetimeof
the study 567 diagnoses of non-Hodgkin’s Lymphoma wereISRN Oncology 3
Table 2: Clinical features of the patients.
Parameters Frequency (%)
Gender
Male 11 (45.8)
Female 13 (54.2)
Age (mean) 60 (range 15–86)
Stage
I/II 13 (45.8)
III/IV 6 (25)
B symptoms 12 (50)
Performance status
<2 23 (95.8)
≥21 ( 4 . 2 )
Serum LDH
Normal 16 (66.7)
Elevated 2 (8.3)
IPI
0 and 1 15 (62.5)
22 ( 8 . 3 )
31 ( 4 . 2 )
4a n d5 0
LDH: lactate dehydrogenase; IPI: International Prognostic Index.
made in the study institution. Of these, 253 were classiﬁed
as DLBCL (44.6%). Twenty-six diagnoses of DLBCL of the
palatine tonsils were made (4.6% of the total amount of
DLBCL), and for this present work 24 cases of DLBCL of the
palatine tonsils were studied, due to the exclusion criteria.
Table 2 shows the characteristics of the study patients.
Most of the patients were treated with a schema based on
anthracycline (CHOP or similar ones). The average follow-
up time of the patients was 43 months (range 1 to 104
months). The overall and event-free survival rates were on
average of 43.5 months to 39.5 months, respectively. Most
of the patients presented a low-risk IPI (Table 2), and, if
compared to patients with none or 1 factor versus >1f a c t o r ,
thisindexdidnotsigniﬁcantlyinﬂuencetheOS(71.6months
versus 31 months, P = 0.30, resp.) and the EFS (71.2 months
versus 30 months, P = 0.26, resp.) of the patients.
3.2. Lymphocyte Count at the Time of Diagnosis. The
mean lymphocyte count at the time of diagnosis was
1.980cells/mm3, varying between 354 and 3.922cells/mm3,
and 18.2% of the patients presented a lymphocyte count
<1.000cells/mm3. Patients with a lymphocyte count at the
time of diagnosis ≥1.000cells/mm3 presented OS (74.9
months versus 16 months) and EFS (74.7 months versus
8.2 months) signiﬁcantly greater than patients with a count
lower than this value (P = 0.005 and P = 0.001, resp.)
(Figure 1).
3.3. Immunohistochemistry. According to the algorithm of
Hans et al. [8], 10 patients were classiﬁed with GC proﬁle
(41.6%),and14wereclassiﬁedwithnon-GCproﬁle(58.4%).
Patients with GC proﬁle presented better OS (64.2 versus
46.5 months) and EFS (63.5 months versus 46.1 months)
than patients with non-GC proﬁle, although with no statisti-
cal signiﬁcance (P = 0.36 and P = 0.33, resp.). The isolated
positivityforthemarkersusedintheHansalgorithm(CD10,
Bcl-6andMUM-1,Figures2(a),2(b)and2(c),resp.)alsodid
not have signiﬁcant inﬂuence on patients’ survival rates.
The Bcl-2 protein expression (Figure 2(d))w a sf o u n di n
54.2% of the patients, and these were signiﬁcantly older than
the patients who were negative (65 versus 44 years old, resp.,
P = 0.02). Patients who were positive for Bcl-2 presented
signiﬁcant worse OS (38 months versus 80.8 months, resp.)
and EFS (37.6 months versus 79.1 months, resp.) rates than
negative patients (P = 0.03 and P = 0.04, resp. (Figure 3)).
The p53 protein expression was found in 45.8% of the
patients with predominance of the male gender (P = 0.03)
and young patients (mean age of 49 years in positive patients
versus 63 years in negative patients, P = 0.08). Patients with
p53 protein expression presented greater OS and EFS rates
than negative patients (68.6 months versus 43.3 months and
67.1 months versus 43.3 months, resp.), but there was no
statistical signiﬁcance (P = 0.22 and P = 0.26, resp.). The
mean Ki67 was 60%, varying from 30 to 100%. There was no
CD5 expression in any of the patients studied.
3.4.InSituHybridization. Allthepatientspresentednegative
in situ hybridization for EBER-1 and 2 transcription of EBV.
4. Discussion
Among the non-Hodgkin’s lymphomas, we observed a
DLBCL frequency similar to other studied series; however,
the palatine tonsils were mostly attacked at a slightly greater
frequency than that referred to in the literature [1, 2].
Similar to other studies, we observed a predominance of B
lymphomas (mainly DLBCL) in this site, as well as more
advanced age at the time of diagnosis, around 60 years [22].
We observed a predominance of tonsil lymphoma
patients and low-risk IPI. When observed alone, the IPI did
not show any signiﬁcance to predict survival rates, and this
index might not be the most adequate prognostic factor for
patients with extranodal lymphoma. However, the reduced
number of patients in this study may have had an inﬂuence
on this analysis.
Recent studies have shown the lymphocyte count at the
timeofdiagnosiswithaprognosticfactorinDLBCL[12,13],
as already shown in other hematological neoplasias such
as Hodgkin’s lymphoma [23], follicular lymphoma [24],
a n da c u t em y e l o i dl e u k e m i a[ 25]. In the current study, this
correlationwasalsoobserved,forpatientswithalymphocyte
count ≥1.000cells/mm3 at the time of diagnosis presented
signiﬁcantly greater OS and EFS rates (P =0.005 and P =
0.001, resp.).
DLBCL has several forms of presentation and is a
heterogeneousentityseenascertainIHCmarkerexpressions,
which could give it a better or worse prognosis. Hans
et al. [8] observed that patients classiﬁed as GC proﬁle4 ISRN Oncology
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Figure 1: Overall survival and event-free survival considering lymphocyte count at the time of diagnosis.
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Figure 2: Immunohistochemical aspects of the palatine tonsils DLBCL: positivity for CD10 (a), Bcl-6 (b), MUM-1 (c), and Bcl-2 (d)
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Figure 3: Overall survival and event-free survival considering Bcl-2 protein status at the time of diagnosis.
(using an algorithm that regards the expression of C10, Bcl-
6, and MUM1 for classiﬁcation) presented better survival
rates than patients with non-GC proﬁle. Patients, in this
study, who had tonsil lymphoma and GC proﬁle, were
observed as having better survival rates; however, a statistical
signiﬁcance was not reached, possibly due to the small
number of patients. The isolated expression of algorithmic
immunohistochemical markers did not show a correlation
with survival rates.
In a more consistent manner, the Bcl-2 expression in
the pre-Rituximab era has proven to be an unfavorable
prognostic factor [9]. In the present study this ﬁnding was
conﬁrmed, for this protein expression was linked to worse
GS and EFS rates. In these patients, the Bcl-2 expression was
present in a signiﬁcant way in older patients (P = 0.02),
whichmighthaveinﬂuencedOSandEFSratesnegativelydue
to the combination of both factors.
Still quite a controversial issue is the prognostic value
of the p53 protein expression in patients with DLBCL. In
two other Brazilian studies that researched this correlation
[26, 27], only one was able to show a signiﬁcant diﬀerence in
OS [26]. In this current study, positivity was associated with
better OS (with no statistical signiﬁcance), and the patients
whowerepositive forp53 tendedtobeyounger,whichmight
have inﬂuenced this observation.
In the present study all the patients were negative for
the CD5 marker. The expression of this marker has been
reported as between 5%–10% of the patients who have de
novo DLBCL, granting a worse prognosis [10]. Due to the
negativity we were unable to evaluate this data. However,
in another study involving patients with DLBCL of the
respiratory-digestive tract, the 17 patients with palatine
tonsil lymphoma were also negative for CD5 [28], similar to
the ﬁndings of this study.
Several studies in the literature have demonstrated the
association between EBV infection and some subtypes of
non-Hodgkin’s lymphoma [15, 17]. In the patients with
diﬀuse large B-cell lymphoma, this association is undergoing
conﬁrmation, with the appearance of many studies seeking
to reinforce the association with EBV. There is even a
correlation with the prognosis of these lymphomas, which
is an unfavorable prognostic factor in EBV-positive patients,
presenting worse treatment response, as well as worse overall
s u r v i v a l ,a n de v e n t - f r e es u r v i v a lr a t e s[ 15].
No association was found between EBV infection and
DLBCL in the patients of this study. This data is diﬀerent
from what was found by Park et al., who studied 380 patients
with DLBCL, where 9% presented EBV infection [15]. Also,
Bahnassyetal.showedEBVinfectionin90%oftheﬁftycases
of head and neck NHL studied in Egypt [17]. Although it
was shown previously that the tonsils of Brazilian children
had signiﬁcantly more EBV-infected cells than the tonsils of
German children [18], the negativity for EBV infection was
found by Wong et al. when they studied 17 patients with
palatine tonsil DLBCL in Malaysia [28].
Weconcludethat,inourmidst,thepalatinetonsildiﬀuse
large B-cell lymphomas predominantly presented a non-GC
proﬁle and were not associated with EBV infection. The
factors that negatively inﬂuenced the OS and EFS rates of
these patients were the lymphocyte count at the time of
diagnosis <1.000/mm3 and the Bcl-2 protein expression.
New studies are necessary to attempt to explain the etiology
of these lymphomas and to identify other prognostic factors.6 ISRN Oncology
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